Across disease sites, including lung cancer and other solid tumors, patients who experience irAEs while on therapy with anti‐PD‐1 and anti‐PD‐L1 antibodies have been documented to experience improved outcomes as measured by ORR, progression‐free survival (PFS), and overall survival (OS).21, 22, 23, 24, 25, 26, 27. This evidence concerns the gene CD274 and lung carcinoma.